Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21)

Autor: Andrés Poveda, Anne Floquet, Jonathan A Ledermann, Rebecca Asher, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Sandro Pignata, Michael Friedlander, Alessandra Baldoni, Tjoung-Won Park-Simon, Kenji Tamura, Gabe S Sonke, Alla Lisyanskaya, Jae-Hoon Kim, Elias Abdo Filho, Tsveta Milenkova, Elizabeth S Lowe, Phil Rowe, Ignace Vergote, Eric Pujade-Lauraine, Tomasz Byrski, Patricia Pautier, Philipp Harter, Nicoletta Colombo, Giovanni Scambia, Maria Nicoletto, Fiona Nussey, Andrew Clamp, Richard Penson, Amit Oza, Andrés Poveda Velasco, Manuel Rodrigues, Jean-Pierre Lotz, Frédéric Selle, Isabelle Ray-Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare Scott, Mayu Yunokawa, Jacques Medioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie-Christine Kaminsky, Béatrice Weber, Alain Lortholary, Christine Parkinson, Jonathan Ledermann, Sarah Williams, Susana Banerjee, Jonathan Cosin, James Hoffman, Marie Plante, Allan Covens, Gabe Sonke, Florence Joly, Holger Hirte, Amnon Amit, Koji Matsumoto, Sergei Tjulandin, Jae Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David O'Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, Maria Pilar Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez De Liaño Lista, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella Ottevanger, Joo-Hyun Nam, Elias Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie McKenzie, Gustavo Rodriguez, Deborah Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan Davidson, Stephen Welch, Limor Helpman, Ami Fishman, Ilan Bruchim, Magdalena Sikorska, Anna Słowińska, Wojciech Rogowski, Mariusz Bidziński, Beata Śpiewankiewicz, Antonio Casado Herraez, César Mendiola Fernández, Martina Gropp-Meier, Toshiaki Saito, Kazuhiro Takehara, Takayuki Enomoto, Hidemichi Watari, Chel Hun Choi, Byoung-Gie Kim, Jae Weon Kim, Roberto Hegg

Publikováno v: Lancet Oncology, 22, 5, pp. 620-631
Lancet Oncology, 22, 620-631
The Lancet Oncology, 22(5), 620-631. Lancet Publishing Group

Contains fulltext : 241226.pdf (Publisher’s version ) (Closed access) BACKGROUND: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously been shown to extend progression-free survival versus placebo when given to patients with re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::327550b0b53fe7a798b4b4246c0e4f41
https://doi.org/10.1016/s1470-2045(21)00073-5

Clinical benefit of breakthrough cancer drugs approved by the United States Food and Drug Administration

Autor: Maria Borrell, Aaron S. Kesselheim, Thomas J Hwang, Eitan Amir, Ignasi Gich Saladich, Ariadna Tibau Martorell, Marta Andrés, Consolacion Molto, Agust Barnadas

Publikováno v: Journal of Clinical Oncology. 37:6513-6513

6513 Background: The Breakthrough Therapy program was established in July 2012 to expedite drug development and approval by the FDA. We compared the characteristics of clinical trials leading to FDA approval as well as the magnitude of clinical benef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f8316b7f8ff67c8acb836cfddb6cfb98
https://doi.org/10.1200/jco.2019.37.15_suppl.6513

First results of a prospective registry in unresectable locally advanced or metastatic breast cancer patients: GEICAM/2014-03 (RegistEM)

Autor: Álvaro Rodríguez-Lescure, Mireia Margeli Vila, Purificación Martínez, Carlos Poblete Jara, Ariadna Tibau Martorell, Silvia Antolín Novoa, Ángel L Guerrero, J. Norberto Batista, Ignasi Tusquets, Isabel Alvarez, Federico Rojo, Jose Luis Alonso Romero, Sofía Ruíz, Jose Ignacio Chacon, Juan José Miralles, Antonio Antón, Sara López-Tarruella, Silvia Varela Ferreiro, Susana Bezares, César A. Rodríguez

Publikováno v: Journal of Clinical Oncology. 37:1077-1077

1077 Background: In Spain there is limited prospective data for unresectable locally advanced breast cancer (ULABC) or metastatic breast cancer (MBC) patients (pts) treated as per clinical practice. RegistEM study will provide epidemiological, pathol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::63dc21b138e17b551e33d0b98e3a3693
https://doi.org/10.1200/jco.2019.37.15_suppl.1077

Post-surgical highly sensitive C-reactive protein (hsCRP) and prognosis in early stage in breast cancer (BC)

Autor: Marguerite Ennis, Ariadna Tibau Martorell, Pamela J. Goodwin

Publikováno v: Journal of Clinical Oncology. 31:550-550

550 Background: Obesity, commonly associated with inflammation, is associated with poor prognosis in BC. Previous research suggests CRP, an obesity-associated marker of systemic inflammation, may mediate the adverse prognostic effects of obesity and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f5dd0e96af96e6029fccc9384d139c14
https://doi.org/10.1200/jco.2013.31.15_suppl.550

Feasibility of sentinel node biopsy in patients with locally advanced breast cancer after neoadjuvant therapy: A pilot study

Autor: Laura Lopez Vilaro, Josep Maria Sabaté, María Jesús Quintana, Antonio Moral, Montserrat Estorch, Enric Capdevila, Agust Barnadas, Rosa Pineda, Belén Ojeda, Ariadna Tibau Martorell, Joan Duch, Enrique Lerma, M. Carmen Alonso, Teresa Ramón y Cajal

Publikováno v: Journal of Clinical Oncology. 30:1120-1120

1120 Background: Sentinel lymph node biopsy (SLNB) is a widely used staging method for patients with early breast cancer. Neoadjuvant Therapy (NT) modifies the anatomical conditions in the breast and axilla, and thus reliability of SLNB after NT rema

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4bfa352a29de4f875348beec55e82eb3
https://doi.org/10.1200/jco.2012.30.15_suppl.1120